Medical - Healthcare Information Services
Build Your Comparison
Side-by-side financial analysisStock Comparison
FORA vs CSGP vs Z vs INFU vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Real Estate - Services
Internet Content & Information
Medical - Instruments & Supplies
Banks - Diversified
FORA vs CSGP vs Z vs INFU vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Real Estate - Services | Internet Content & Information | Medical - Instruments & Supplies | Banks - Diversified |
| Market Cap | $68M | $12.77B | $7.72B | $190M | $908.57B |
| Revenue (TTM) | $30M | $3.41B | $2.69B | $142M | $280.33B |
| Net Income (TTM) | $-5M | $25M | $61M | $8M | $57.05B |
| Gross Margin | 46.8% | 77.4% | 73.3% | 56.7% | 60.0% |
| Operating Margin | -13.4% | -0.8% | 0.4% | 9.1% | 25.9% |
| Forward P/E | — | 22.1x | 14.1x | 22.2x | 14.6x |
| Total Debt | $12K | $1.14B | $536M | $3M | $942.38B |
| Cash & Equiv. | $13M | $1.73B | $773M | $3M | $343.34B |
FORA vs CSGP vs Z vs INFU vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Forian Inc. (FORA) | 100 | 21.5 | -78.5% |
| CoStar Group, Inc. (CSGP) | 100 | 42.1 | -57.9% |
| Zillow Group, Inc. … (Z) | 100 | 34.2 | -65.8% |
| InfuSystem Holdings… (INFU) | 100 | 49.8 | -50.2% |
| JPMorgan Chase & Co. (JPM) | 100 | 205.8 | +105.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FORA vs CSGP vs Z vs INFU vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FORA has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- beta 0.21
- Rev growth 50.1%, EPS growth 23.0%, 3Y rev CAGR 22.6%
- Lower volatility, beta 0.21, Low D/E 0.0%, current ratio 2.97x
- Beta 0.21, current ratio 2.97x
Among these 5 stocks, CSGP doesn't own a clear edge in any measured category.
Z is the clearest fit if your priority is value.
- Lower P/E (14.1x vs 14.6x)
INFU is the #2 pick in this set and the best alternative if momentum and efficiency is your priority.
- +52.2% vs CSGP's -62.1%
- 7.9% ROA vs FORA's -11.8%, ROIC 12.5% vs -7.5%
JPM ranks third and is worth considering specifically for long-term compounding.
- 481.2% 10Y total return vs INFU's 240.1%
- 20.4% margin vs FORA's -17.0%
- 1.8% yield; 15-year raise streak; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 50.1% revenue growth vs JPM's 3.3% | |
| Value | Lower P/E (14.1x vs 14.6x) | |
| Quality / Margins | 20.4% margin vs FORA's -17.0% | |
| Stability / Safety | Beta 0.21 vs INFU's 1.22, lower leverage | |
| Dividends | 1.8% yield; 15-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +52.2% vs CSGP's -62.1% | |
| Efficiency (ROA) | 7.9% ROA vs FORA's -11.8%, ROIC 12.5% vs -7.5% |
FORA vs CSGP vs Z vs INFU vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FORA vs CSGP vs Z vs INFU vs JPM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 2 of 6 categories
INFU leads 2 • FORA leads 0 • CSGP leads 0 • Z leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 9328.3x FORA's $30M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to FORA's -17.0%. On growth, CSGP holds the edge at +22.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $30M | $3.4B | $2.7B | $142M | $280.3B |
| EBITDAEarnings before interest/tax | -$4M | $278M | $221M | $26M | $81.4B |
| Net IncomeAfter-tax profit | -$5M | $25M | $61M | $8M | $57.0B |
| Free Cash FlowCash after capex | $2M | $241M | $431M | $20M | $100.9B |
| Gross MarginGross profit ÷ Revenue | +46.8% | +77.4% | +73.3% | +56.7% | +60.0% |
| Operating MarginEBIT ÷ Revenue | -13.4% | -0.8% | +0.4% | +9.1% | +25.9% |
| Net MarginNet income ÷ Revenue | -17.0% | +0.7% | +2.3% | +5.6% | +20.4% |
| FCF MarginFCF ÷ Revenue | +7.8% | +7.1% | +16.0% | +14.3% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.9% | +22.5% | +18.4% | -3.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -2.0% | +127.7% | +5.1% | +5.9% | +16.0% |
Valuation Metrics
INFU leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 16.2x trailing earnings, JPM trades at a 99% valuation discount to CSGP's 1814.5x P/E. On an enterprise value basis, INFU's 7.5x EV/EBITDA is more attractive than CSGP's 71.6x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $68M | $12.8B | $7.7B | $190M | $908.6B |
| Enterprise ValueMkt cap + debt − cash | $55M | $12.2B | $7.5B | $190M | $1.51T |
| Trailing P/EPrice ÷ TTM EPS | -23.48x | 1814.46x | 354.81x | 30.39x | 16.22x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 22.11x | 14.10x | 22.16x | 14.60x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 0.92x |
| EV / EBITDAEnterprise value multiple | — | 71.63x | 28.65x | 7.55x | 18.52x |
| Price / SalesMarket cap ÷ Revenue | 2.24x | 3.93x | 2.99x | 1.33x | 3.25x |
| Price / BookPrice ÷ Book value/share | 2.27x | 1.52x | 1.67x | 3.47x | 2.51x |
| Price / FCFMarket cap ÷ FCF | 23.49x | 311.35x | 32.83x | 7.97x | 9.01x |
Profitability & Efficiency
INFU leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-17 for FORA. FORA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), INFU scores 8/9 vs JPM's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -17.2% | +0.3% | +1.3% | +14.0% | +15.9% |
| ROA (TTM)Return on assets | -11.8% | +0.2% | +1.1% | +7.9% | +1.3% |
| ROICReturn on invested capital | -7.5% | -0.9% | -0.5% | +12.5% | +4.5% |
| ROCEReturn on capital employed | -8.2% | -0.8% | -0.6% | +14.3% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 7 | 8 | 5 |
| Debt / EquityFinancial leverage | 0.00x | 0.14x | 0.11x | 0.06x | 2.60x |
| Net DebtTotal debt minus cash | -$13M | -$589M | -$237M | $241,000 | $599.0B |
| Cash & Equiv.Liquid assets | $13M | $1.7B | $773M | $3M | $343.3B |
| Total DebtShort + long-term debt | $12,137 | $1.1B | $536M | $3M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | -48.78x | 1.58x | 5.22x | 15.54x | 0.74x |
Total Returns (Dividends Reinvested)
JPM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $23,548 today (with dividends reinvested), compared to $1,735 for FORA. Over the past 12 months, INFU leads with a +52.2% total return vs CSGP's -62.1%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.7% vs CSGP's -29.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +2.4% | -54.1% | -51.3% | +12.3% | +0.8% |
| 1-Year ReturnPast 12 months | +2.4% | -62.1% | -52.5% | +52.2% | +20.9% |
| 3-Year ReturnCumulative with dividends | -7.3% | -64.7% | -32.9% | -7.6% | +138.8% |
| 5-Year ReturnCumulative with dividends | -82.7% | -65.7% | -72.3% | -50.2% | +135.5% |
| 10-Year ReturnCumulative with dividends | -90.5% | +43.4% | -7.6% | +240.1% | +481.2% |
| CAGR (3Y)Annualised 3-year return | -2.5% | -29.3% | -12.5% | -2.6% | +33.7% |
Risk & Volatility
Evenly matched — FORA and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
FORA is the less volatile stock with a 0.21 beta — it tends to amplify market swings less than INFU's 1.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 96.2% from its 52-week high vs CSGP's 30.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.21x | 0.45x | 1.15x | 1.22x | 0.87x |
| 52-Week HighHighest price in past year | $2.71 | $97.43 | $93.88 | $11.04 | $338.09 |
| 52-Week LowLowest price in past year | $1.64 | $29.53 | $31.48 | $5.38 | $269.72 |
| % of 52W HighCurrent price vs 52-week peak | +80.1% | +30.9% | +34.2% | +85.3% | +96.2% |
| RSI (14)Momentum oscillator 0–100 | 63.8 | 31.0 | 31.1 | 41.5 | 72.1 |
| Avg Volume (50D)Average daily shares traded | 40K | 7.0M | 4.0M | 172K | 7.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CSGP as "Buy", Z as "Hold", INFU as "Buy", JPM as "Buy". Consensus price targets imply 111.0% upside for Z (target: $68) vs 4.5% for JPM (target: $340). JPM is the only dividend payer here at 1.83% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | — | $61.18 | $67.75 | $15.00 | $339.75 |
| # AnalystsCovering analysts | — | 25 | 46 | 3 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +1.8% |
| Dividend StreakConsecutive years of raises | — | — | — | — | 15 |
| Dividend / ShareAnnual DPS | — | — | — | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +4.5% | +8.7% | +5.8% | +3.8% |
JPM leads in 2 of 6 categories (Income & Cash Flow, Total Returns). INFU leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
FORA vs CSGP vs Z vs INFU vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FORA or CSGP or Z or INFU or JPM a better buy right now?
For growth investors, Forian Inc.
(FORA) is the stronger pick with 50. 1% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate CoStar Group, Inc. (CSGP) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FORA or CSGP or Z or INFU or JPM?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 2x versus CoStar Group, Inc. at 1814. 5x. On forward P/E, Zillow Group, Inc. Class C is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — FORA or CSGP or Z or INFU or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +135. 5%, compared to -82. 7% for Forian Inc. (FORA). Over 10 years, the gap is even starker: JPM returned +481. 2% versus FORA's -90. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FORA or CSGP or Z or INFU or JPM?
By beta (market sensitivity over 5 years), Forian Inc.
(FORA) is the lower-risk stock at 0. 21β versus InfuSystem Holdings, Inc. 's 1. 22β — meaning INFU is approximately 480% more volatile than FORA relative to the S&P 500. On balance sheet safety, Forian Inc. (FORA) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — FORA or CSGP or Z or INFU or JPM?
By revenue growth (latest reported year), Forian Inc.
(FORA) is pulling ahead at 50. 1% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -95. 1% for CoStar Group, Inc.. Over a 3-year CAGR, FORA leads at 22. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FORA or CSGP or Z or INFU or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -9. 5% for Forian Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -8. 2% for FORA. At the gross margin level — before operating expenses — CSGP leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FORA or CSGP or Z or INFU or JPM more undervalued right now?
On forward earnings alone, Zillow Group, Inc.
Class C (Z) trades at 14. 1x forward P/E versus 22. 2x for InfuSystem Holdings, Inc. — 8. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for Z: 111. 0% to $67. 75.
08Which pays a better dividend — FORA or CSGP or Z or INFU or JPM?
In this comparison, JPM (1.
8% yield) pays a dividend. FORA, CSGP, Z, INFU do not pay a meaningful dividend and should not be held primarily for income.
09Is FORA or CSGP or Z or INFU or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Both have compounded well over 10 years (JPM: +481. 2%, Z: -7. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FORA and CSGP and Z and INFU and JPM?
These companies operate in different sectors (FORA (Healthcare) and CSGP (Real Estate) and Z (Communication Services) and INFU (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: FORA is a small-cap high-growth stock; CSGP is a mid-cap high-growth stock; Z is a small-cap high-growth stock; INFU is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while FORA, CSGP, Z, INFU do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.